293 related articles for article (PubMed ID: 33606577)
1. The adjuvanted recombinant zoster vaccine is efficacious and safe in Asian adults ≥ 50 years of age: a sub-cohort analysis of the ZOE-50 and ZOE-70 randomized trials.
Kim JH; Diaz-Decaro J; Jiang N; Hwang SJ; Choo EJ; Co M; Hastie A; Hui DSC; Irimajiri J; Lee J; Leung EM; Tang H; Tsuru T; Watson P; Wu Z; Yu CJ; Yuan Y; Zahaf T; Cunningham AL; Schuind A
Hum Vaccin Immunother; 2021 Jul; 17(7):2050-2057. PubMed ID: 33606577
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of the adjuvanted recombinant zoster vaccine (RZV) by sex, geographic region, and geographic ancestry/ethnicity: A post-hoc analysis of the ZOE-50 and ZOE-70 randomized trials.
Willer DO; Oostvogels L; Cunningham AL; Gervais P; Gorfinkel I; Hyung Kim J; Talarico C; Wascotte V; Zahaf T; Colindres R; Schuind A;
Vaccine; 2019 Oct; 37(43):6262-6267. PubMed ID: 31537443
[TBL] [Abstract][Full Text] [Related]
3. Efficacy, reactogenicity, and safety of the adjuvanted recombinant zoster vaccine for the prevention of herpes zoster in Chinese adults ≥ 50 years: A randomized, placebo-controlled trial.
Alexandra Echeverria Proano D; Zhu F; Sun X; Zoco J; Soni J; Parmar N; Ali SO;
Hum Vaccin Immunother; 2024 Dec; 20(1):2351584. PubMed ID: 38838170
[TBL] [Abstract][Full Text] [Related]
4. The comparative efficacy and safety of herpes zoster vaccines: A network meta-analysis.
McGirr A; Widenmaier R; Curran D; Espié E; Mrkvan T; Oostvogels L; Simone B; McElhaney JE; Burnett H; Haeussler K; Thano A; Wang X; Newson RS
Vaccine; 2019 May; 37(22):2896-2909. PubMed ID: 30982636
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older.
Cunningham AL; Lal H; Kovac M; Chlibek R; Hwang SJ; Díez-Domingo J; Godeaux O; Levin MJ; McElhaney JE; Puig-Barberà J; Vanden Abeele C; Vesikari T; Watanabe D; Zahaf T; Ahonen A; Athan E; Barba-Gomez JF; Campora L; de Looze F; Downey HJ; Ghesquiere W; Gorfinkel I; Korhonen T; Leung E; McNeil SA; Oostvogels L; Rombo L; Smetana J; Weckx L; Yeo W; Heineman TC;
N Engl J Med; 2016 Sep; 375(11):1019-32. PubMed ID: 27626517
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases: a pooled post hoc analysis on two parallel randomized trials.
Dagnew AF; Rausch D; Hervé C; Zahaf T; Levin MJ; Schuind A;
Rheumatology (Oxford); 2021 Mar; 60(3):1226-1233. PubMed ID: 32910152
[TBL] [Abstract][Full Text] [Related]
7. Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials.
Oostvogels L; Heineman TC; Johnson RW; Levin MJ; McElhaney JE; Van den Steen P; Zahaf T; Dagnew AF; Chlibek R; Diez-Domingo J; Gorfinkel IS; Hervé C; Hwang SJ; Ikematsu H; Kalema G; Lal H; McNeil SA; Mrkvan T; Pauksens K; Smetana J; Watanabe D; Weckx LY; Cunningham AL
Hum Vaccin Immunother; 2019; 15(12):2865-2872. PubMed ID: 31216205
[TBL] [Abstract][Full Text] [Related]
8. Safety profile of the adjuvanted recombinant zoster vaccine: Pooled analysis of two large randomised phase 3 trials.
López-Fauqued M; Campora L; Delannois F; El Idrissi M; Oostvogels L; De Looze FJ; Diez-Domingo J; Heineman TC; Lal H; McElhaney JE; McNeil SA; Yeo W; Tavares-Da-Silva F;
Vaccine; 2019 Apr; 37(18):2482-2493. PubMed ID: 30935742
[TBL] [Abstract][Full Text] [Related]
9. Public health impact model estimating the impact of introducing an adjuvanted recombinant zoster vaccine into the UK universal mass vaccination programme.
van Oorschot DAM; Hunjan M; Bracke B; Lorenc S; Curran D; Starkie-Camejo H
BMJ Open; 2019 May; 9(5):e025553. PubMed ID: 31061027
[TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy data for the recombinant zoster vaccine: impact on public health and cost effectiveness in Germany.
Curran D; Van Oorschot D; Matthews S; Hain J; Salem AE; Schwarz M
Hum Vaccin Immunother; 2021 Dec; 17(12):5296-5303. PubMed ID: 34905463
[TBL] [Abstract][Full Text] [Related]
11. Safety of the adjuvanted recombinant zoster vaccine in adults aged 50 years or older. A phase IIIB, non-randomized, multinational, open-label study in previous ZOE-50 and ZOE-70 placebo recipients.
Ocran-Appiah J; Boutry C; Hervé C; Soni J; Schuind A;
Vaccine; 2021 Jan; 39(1):6-10. PubMed ID: 33277059
[TBL] [Abstract][Full Text] [Related]
12. Adjuvanted recombinant zoster vaccine decreases herpes zoster-associated pain and the use of pain medication across 3 randomized, placebo-controlled trials.
Kim JH; Johnson R; Kovac M; Cunningham AL; Amakrane M; Sullivan KM; Dagnew AF; Curran D; Schuind A
Pain; 2023 Apr; 164(4):741-748. PubMed ID: 36066965
[TBL] [Abstract][Full Text] [Related]
13. Natural History of Herpes Zoster in the Placebo Groups of Three Randomized Phase III Clinical Trials.
Curran D; Matthews S; Boutry C; Lecrenier N; Cunningham AL; Schmader K
Infect Dis Ther; 2022 Dec; 11(6):2265-2277. PubMed ID: 36322332
[TBL] [Abstract][Full Text] [Related]
14. Recombinant zoster vaccine in immunocompetent and immunocompromised adults: A review of clinical studies.
Mwakingwe-Omari A; Lecrenier N; Naficy A; Curran D; Posiuniene I
Hum Vaccin Immunother; 2023 Dec; 19(3):2278362. PubMed ID: 37965770
[TBL] [Abstract][Full Text] [Related]
15. Complications of herpes zoster in immunocompetent older adults: Incidence in vaccine and placebo groups in two large phase 3 trials.
Kovac M; Lal H; Cunningham AL; Levin MJ; Johnson RW; Campora L; Volpi A; Heineman TC;
Vaccine; 2018 Mar; 36(12):1537-1541. PubMed ID: 29463421
[TBL] [Abstract][Full Text] [Related]
16. Public health impact of herpes zoster vaccination on older adults in Singapore: a modeling study.
Oh H; Tan C; Williams C; Giannelos N; Ng C
Hum Vaccin Immunother; 2024 Dec; 20(1):2348839. PubMed ID: 38804600
[TBL] [Abstract][Full Text] [Related]
17. Public health impact of herpes zoster vaccination on older adults in Hong Kong.
Chan PKS; Wong MCS; Chan M; Ching K; Giannelos N; Ng C
Hum Vaccin Immunother; 2023 Dec; 19(1):2176065. PubMed ID: 36854447
[TBL] [Abstract][Full Text] [Related]
18. Recombinant Zoster Vaccine (Shingrix
Syed YY
Drugs Aging; 2018 Dec; 35(12):1031-1040. PubMed ID: 30370455
[TBL] [Abstract][Full Text] [Related]
19. Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice.
Stadtmauer EA; Sullivan KM; El Idrissi M; Salaun B; Alonso Alonso A; Andreadis C; Anttila VJ; Bloor AJ; Broady R; Cellini C; Cuneo A; Dagnew AF; Di Paolo E; Eom H; González-Rodríguez AP; Grigg A; Guenther A; Heineman TC; Jarque I; Kwak JY; Lucchesi A; Oostvogels L; Polo Zarzuela M; Schuind AE; Shea TC; Sinisalo UM; Vural F; Yáñez San Segundo L; Zachée P; Bastidas A
Hum Vaccin Immunother; 2021 Nov; 17(11):4144-4154. PubMed ID: 34406911
[TBL] [Abstract][Full Text] [Related]
20. Recombinant Zoster Vaccine Is Efficacious and Safe in Frail Individuals.
Curran D; Kim JH; Matthews S; Dessart C; Levin MJ; Oostvogels L; Riley ME; Schmader KE; Cunningham AL; McNeil SA; Schuind AE; Andrew MK;
J Am Geriatr Soc; 2021 Mar; 69(3):744-752. PubMed ID: 33197294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
